The FINANCIAL -- The Journal of the American Medical Association published a Phase III study that showed significant survival benefits for patients meeting the study inclusion criteria who received three years of treatment with Glivec after surgery to remove KIT-positive gastrointestinal stromal tumors compared to one year of treatment.

The FINANCIAL -- The European Medicines Agency released a guidance on increased transparency and access to information included in companies' applications for marketing authorisation.

The FINANCIAL -- Bayer HealthCare announced that the company will present latest preclinical data that introduce investigational compounds for both therapy and imaging in its oncology pipeline at the American Association for Cancer Research 103rd Annual Meeting, March 31 - April 4, 2012, in Chicago, IL.

The FINANCIAL -- Bayer HealthCare Company Ltd and Tsinghua University in Beijing, China, are expanding their joint research partnership relating to the Bayer-Tsinghua Joint Research Center for Innovative Drug Discovery.